Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

David P. Steensma, Gordon W. Dewald, Terra L. Lasho et al. · Blood · 2005 · 466 citations · Full text

Medicine, Genetics, Hematology +8

X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis

Ross L. Levine, Claude Bélisle, Martha Wadleigh et al. · Blood · 2006 · 237 citations · Full text

Life Sciences, Hematology, Pathology +12

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation

Hadrian Szpurka, Ramón V. Tiu, Gurunathan Murugesan et al. · Blood · 2006 · 207 citations · Full text

Medicine, Genetics, Hematology +13

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Annette Schmitt‐Graeff, Swee‐Sen Teo, Manfred Olschewski et al. · Haematologica · 2007 · 119 citations · Full text

Medicine, Genetics, Hematology +16

The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)

Marjorie Boissinot, Richard Garand, M. Hamidou et al. · Blood · 2006 · 65 citations

Medicine, Hematology, Molecular Genetics +13